منابع مشابه
Generic medicines are not substandard medicines.
1 who work for the industry-funded Hudson Institute, advocate the use of patented drugs, pointing to what they say are risks associated with generic drugs. They confuse generic drugs with old, substandard, ineffective, and counterfeit drugs. Generic does not mean old. The 1996 World Trade Organisation (WTO) Agreements mandate all member countries to provide 20-year patent protection for medicin...
متن کاملClinical Studies – Generic Medicines
Clinical testing is not the only way to discover drug effects on people. That is the reason controlled clinical trials are the only legal basis for central regulatory agencies in each country, such as FDA, to conclude that a new drug has clinical effectiveness for a drug or biologic. Before clinical testing begins, researchers analyze the drug’s main physical and chemical properties in the labo...
متن کاملFirst Innovative Medicines Initiative Ebola projects launched.
The IMI Ebola+ programme was created in response to the ongoing Ebola outbreak in western Africa. The projects bring together partners from the pharmaceutical and diagnostics industries, public health bodies, academia, aid organisations, and small biotech companies in Europe, Africa and the United States. Previous experience at IMI has shown that consortia of this kind, which bring together div...
متن کاملWho can pay for innovative medicines?
I nnovative medicines are of vital importance to the patients affected with one of the many acute or chronic illnesses, for which current treatments are often suboptimal. In particular chronic non-communicable diseases are becoming more prevalent, and this is even seen as a real crisis requiring United Nations action [1, 2]. It is widely known that, although the investments of the pharmaceutica...
متن کاملAccess to innovative oncology medicines in Europe
This article intends to give an overview about developments in European Regulatory and Health Technology Assessment (HTA) of new cancer drugs. As background information, it will refer to an overview article by Bergmann et al. [1], which pointed out the status and the limitations of the current system. The authors discussed possible steps to improve the interface between regulators and HTA bodie...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the Royal Society of Medicine
سال: 1991
ISSN: 0141-0768,1758-1095
DOI: 10.1177/014107689108400627